About this Course
This course is a recorded (home study version) of the CE Finale Encore Webinars.
Learning Objectives
Upon completion of this application based CE Activity, a pharmacist will be able to:
|
|
|
|
Release and Expiration Dates
Released: December 15, 2023
Expires: December 15, 2026
Course Fee
$17 Pharmacist
ACPE UAN
0009-0000-23-039-H01-P
Session Code
23RW39-TXJ88
Accreditation Hours
1.0 hours of CE
Additional Information
How to Complete Evaluation: When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.
Accreditation Statement
The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-23-039-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.
Grant Funding
There is no grant funding for this activity.
Faculty
C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
- Dr. White has no relationships with ineligible companies
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Content
Post Test
Post Test “TOP 10 Cardiovascular Drugs Used Off Label!!!”
1. Which of the following drugs has been used to enhance the chances of delivering a baby in patients with Factor 5 Leiden and what is the mechanism of benefit?
a) Thiazide diuretics; reduced placental calcium that stops crystalline umbilical cord blockage
b) LMWH; preventing placental thrombosis in patients who are hypercoagulable
c) Disopyramide – decreasing the inotropic effect in hypertrophic cardiomyopathy that leads to placental detachment
2. Which of the following drugs is effective for treating anal fissures and what is the mechanism of action?
a) IV iron; iron deficiency anemia promotes fissure formation so treating it reverses fissure
b) Amiodarone; overactive potassium channels in the anus lead to apoptosis of anal mucosal cells
c) CCBs; Blood vessel dilation enhancing blood flow to targeted areas in the body
3. Which of the following drugs is properly linked to the off-label indication it is commonly used for?
a) Beta-blockers – Raynaud’s phenomenon
b) Prazosin – Nightmares in PTSD patients
c) Clonidine – Stage fright
4. Which of the following drugs is used off label for the treatment of abnormal face and body hair growth in patients and what is the mechanism of action?
a) Spironolactone – blocking the effects of testosterone in several ways
b) Beta-blockers – blocking epinephrine induced follicular stimulation
c) Clonidine – central outflow of norepinephrine causes abnormal hair growth
5. Sally Sue has had atrial fibrillation for several months. Her cardiologist has prescribed several therapies that have been ineffective, and one that is on the drug shortage list and hard to find. Which of the following might the cardiologist use off-label according to the AHA/ACC Guideline?
a) Calcium channel blockers
b) Prazocin
c) Amiodarone
Handouts
VIDEO